Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage

Abstract

Objectives: The stockpiling of neuraminidase inhibitor (NAI) antivirals as a defence against pandemic influenza is a significant public health policy decision that must be made despite a lack of conclusive evidence from randomised controlled trials regarding the effectiveness of NAIs on important clinical end points such as mortality. The objective of this study was to determine whether NAIs should be stockpiled for treatment of pandemic influenza on the basis of current evidence. Methods: A decision model for stockpiling was designed. Data on previous pandemic influenza epidemiology was combined with data on the effectiveness of NAIs in reducing mortality obtained from a recent individual participant meta-analysis using observational data. Evidence synthesis techniques and a bias modelling method for observational data were used to incorporate the evidence into the model. The stockpiling decision was modelled for adults (≥16 years old) and the United Kingdom was used as an example. The main outcome was the expected net benefits of stockpiling in monetary terms. Health benefits were estimated from deaths averted through stockpiling. Results: After adjusting for biases in the estimated effectiveness of NAIs, the expected net benefit of stockpiling in the baseline analysis was £444 million, assuming a willingness to pay of £20,000/QALY ($31,000/QALY). The decision would therefore be to stockpile NAIs. There was a greater probability that the stockpile would not be utilised than utilised. However, the rare but catastrophic losses from a severe pandemic justified the decision to stockpile. Conclusions: Taking into account the available epidemiological data and evidence of effectiveness of NAIs in reducing mortality, including potential biases, a decision maker should stockpile anti-influenza medication in keeping with the postulated decision rule.

Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia

“…Unreliable low-count transcripts in all samples were filtered. Then, a differential expression analysis of the specified STAT3/5 response classes was performed based on the edgeR quasi-likelihood pipeline with sample batch correction [ 18 ]. The genes were called significant at false discovery rate (FDR) = 0.05.…”

A re‐analysis of 150 women's health trials to investigate how the Bayesian approach may offer a solution to the misinterpretation of statistical findings

“…We have used somewhat arbitrary classifications for clinically important and trivial effect sizes 28 . We thus suggest that with appropriate contextual knowledge, clinically important effect sizes should be defined at the planning stage 23 .…”

Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness

“…Additionally, evidence suggests that in-hospital NAI treatment may also be associated with protective effects 43,44 and NAI treatment has been shown to be cost-effective if the benefits of NAI usage are confined only to those treated in hospital. 45 If a pandemic treatment policy was pursued which combined community use of NAIs to prevent hospital admission and NAI treatment of hospitalized patients to reduce mortality, then cost-effectiveness and stockpile strategies across both scenarios would need to be considered. Future research in optimizing NAI distribution to risk groups during a pandemic will further inform the costeffectiveness of stockpiling.…”